Hematology
Bringing New Hope to Hematologic Cancers
Pioneering Early-Phase Research Across the START Network
START is a global leader in early-phase malignant hematology clinical trials, offering unparalleled expertise and access to novel therapies. Our network of world-class investigators, innovative trial designs, and global clinical sites ensures rapid and efficient execution of groundbreaking studies in leukemia, lymphoma, multiple myeloma, and other hematologic malignancies.
The Need for Innovation in Hematology Clinical Research
Hematologic cancers are complex, aggressive, and evolving, requiring innovative treatments that go beyond standard therapies. Despite advancements, many patients with relapsed or refractory disease still face limited treatment options.
- Emerging therapies, including novel immunotherapies, bispecific antibodies, and targeted inhibitors, are redefining hematology treatment.
- Early-phase research plays a critical role in accelerating access to these promising therapies, ensuring patients receive innovative treatments sooner.
As a dedicated early-phase clinical research organization, START is at the forefront of advancing malignant hematology drug development through precision-driven, patient-centered trials.
“Sites that combine expertise in hematological malignancies with experience in First-in-Human Phase 1 trials are relatively rare. Therefore, expanding our focus to include more blood cancer trials is a natural progression of our mission to provide access to patients globally,” said Nick Slack, MBE, Chairman and CEO of START. “
By the Numbers
START's Impact in Hematology
active trials in malignant hematology
Our Commitment to
Advancing Hematology Research
START is actively contributing to groundbreaking hematology research, with our PIs authoring and collaborating on high-impact publications:
Recent Publications & Research Highlights
By:
- Drew W. Rasco, MD, Manish R. Sharma, MD, Midwest, San Antonio, United States
Journal: Invest New Drugs
Published Date: March 14, 2024
By:
- Amita Patnaik, MD, FRCPC, Manish R. Sharma, MD, Midwest, San Antonio, United States
Journal: Clin Ther.
Published Date: February 23, 2024
By:
- Drew W. Rasco, MD, Midwest, Nehal Lakhani, MD, PhD, San Antonio, United States
Journal: ESMO Open
Published Date: February 21, 2024
Why Choose START for Hematology Clinical Trials?
01. Unmatched Early-Phase Expertise
With over 1,500+ early-phase trials completed, START is the most experienced site network for hematology drug development.
02. Seamless Global Trial Execution
One contract, one budget, one process across all START locations ensures faster study activation and efficient enrollment.
03. Access to Diverse Patient Populations
Our global footprint enables sponsors to reach relapsed/refractory, biomarker-driven, and hard-to-treat patient groups.
04. Scientific Leadership & Operational Excellence
Our PIs provide real-time trial insights, ensuring research aligns with the most advanced treatment paradigms.
05. Strong Partnerships
We collaborate with top biopharma sponsors to bring next-generation therapies to patients faster. We also work hand-in-hand with our referring physicians to ensure constant communication about the patients in our care.
Learn More About Our Expertise in Malignant Hematology Research
Whether you are a biopharma sponsor, referring physician, or patient seeking clinical trial options, START is committed to driving the next wave of malignant hematology cancer breakthroughs.
